PMID- 28989576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240109
IS  - 1976-1457 (Print)
IS  - 2005-6168 (Electronic)
IS  - 1976-1457 (Linking)
VI  - 11
IP  - 5
DP  - 2017 Oct
TI  - Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh 
      tissue in type 2 diabetic patients with hypertension.
PG  - 396-401
LID - 10.4162/nrp.2017.11.5.396 [doi]
AB  - BACKGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind 
      study, we evaluated the antihypertensive effects of enzymatic hydrolysate from 
      Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and 
      hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) 
      and placebo (n = 22) were randomly allocated to the study subjects. Each subject 
      ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or 
      placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, 
      systolic and diastolic blood pressure decreased significantly 4 weeks after 
      ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In 
      addition, the SFTH group exhibited a significant decrease in hemoglobin A(1c) 
      with a tendency toward improvement in homeostasis model assessment of insulin 
      resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 
      weeks. No adverse effects were observed in other indexes, including biochemical 
      and hematological parameters in both groups. CONCLUSION: The results of our study 
      suggested that SFTH exerts a regulatory, antihypertensive effect in patients with 
      T2DM and hypertension.
FAU - Ko, Seok-Chun
AU  - Ko SC
AD  - Marine-Integrated Bionics Research Center, Pukyong National University, Busan 
      48513, Korea.
FAU - Jung, Won-Kyo
AU  - Jung WK
AD  - Marine-Integrated Bionics Research Center, Pukyong National University, Busan 
      48513, Korea.
AD  - Department of Biomedical Engineering, and Center for Marine-Integrated Biomedical 
      Technology (BK21 Plus), Pukyong National University, Busan 48513, Korea.
FAU - Lee, Seung-Hong
AU  - Lee SH
AD  - Department of Pharmaceutical Engineering, Soonchunhyang University, 22 
      Soonchunhyangro, Shinchang-myeon, Asan-si, Chungnam 31538, Korea.
FAU - Lee, Dae Ho
AU  - Lee DH
AD  - Department of Internal Medicine, Gachon University Gil Medical Center, 21 
      Namdong-daero 774 road, Incheon 21565, Korea.
FAU - Jeon, You-Jin
AU  - Jeon YJ
AD  - Department of Marine Life Science, Jeju National University, 102 Jejudaehak-ro, 
      Jeju-si, Jeju 63243, Korea.
LA  - eng
PT  - Journal Article
DEP - 20170915
PL  - Korea (South)
TA  - Nutr Res Pract
JT  - Nutrition research and practice
JID - 101311052
PMC - PMC5621362
OTO - NOTNLM
OT  - Aquatic organisms
OT  - antihypertensive agents
OT  - clinical trial
OT  - protein hydrolysates
COIS- CONFLICT OF INTEREST: The authors declare no potential conflicts of interests.
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:01
PMCR- 2017/10/01
CRDT- 2017/10/10 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/05/14 00:00 [revised]
PHST- 2017/07/20 00:00 [accepted]
PHST- 2017/10/10 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:01 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
AID - 10.4162/nrp.2017.11.5.396 [doi]
PST - ppublish
SO  - Nutr Res Pract. 2017 Oct;11(5):396-401. doi: 10.4162/nrp.2017.11.5.396. Epub 2017 
      Sep 15.